Table 1.
Patients’ Demographic and Clinical Characteristics
| n | % | |
|---|---|---|
| Patients | 92 | |
| Sex, male/female | 38/54 | 41.3/58.7 |
| Diagnosis | ||
| Schizophrenia | 73 | 79.4 |
| Schizoaffective disorder | 15 | 16.3 |
| Other | 4 | 4.3 |
| Current smokers | 35 | 38.0 |
| Age (y), median (min-max) | 42 (17–74) | |
| Clozapine daily dose (mg), median (min-max) | 200 (50–700) | |
| Bodyweight (kg), median (min-max) | 76 (51–129) | |
| Serum levels, median (min-max) | ||
| Clozapine (ng/mL) | 232 (23–1400) | |
| Norclozapine (ng/mL) | 156 (16–894) | |
| Clozapine N-oxide (ng/mL) | 90 (0–383) | |
| CYP genotype | ||
| CY2C19* | ||
| *1/*1 | 35 | 38.0 |
| *1/mut | 23 | 25 |
| mut/mut | 2 | 2.2 |
| mut/*17 | 6 | 6.5 |
| *1/*17 | 20 | 21.7 |
| *17/*17 | 6 | 6.5 |
| CYP2D6** | ||
| *1/*1 | 36 | 39.2 |
| *1/mut | 37 | 40.2 |
| mut/mut | 14 | 15.2 |
| *1/*1xN | 5 | 5.4 |
| CYP3A4 | ||
| *1/*1 | 74 | 80.4 |
| *1/*1B | 5 | 5.4 |
| *1/*22 | 13 | 14.2 |
| CYP3A5 | ||
| *1/*3 | 10 | 10.9 |
| *3/*3 | 82 | 89.1 |
| CYP expression | ||
| CYP1A2 | ||
| low expressers | 65 | 70.7 |
| normal expressers | 27 | 29.3 |
| CYP3A4 | ||
| low expressers | 27 | 29.3 |
| normal expressers | 62 | 67.4 |
| high expressers | 3 | 3.3 |
*CYP2C19 mut: *2, *3 and *4; **CYP2D6 mut: *3, *4, *5, *6, *10 and *41.